SCHEMBL22871302

SCHEMBL22871302

BC1(O)c2cc(Cl)ccc2N(S(=O)(=O)c2ccc(C)cc2)CCC1(F)F

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RORC P51449 2/20 0.40
NR1I2 O75469 1/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
TP53 P04637 3/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP2C9 P11712 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20601783 0.88 RORC (0.43) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL31585889 0.88 RORC (0.43) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL20601657 0.85 MAPT (0.43) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL31585948 0.85 MAPT (0.43) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL31586280 0.83 MAPT (0.40) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL20602219 0.83 MAPT (0.40) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL31586047 0.81 MAPT (0.40) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL20601680 0.78 MAPT (0.38) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL20601634 0.77 MAPT (0.40) MAPTLMNASMN1; SMN2RORCNR1I2
SCHEMBL20601907 0.75 MAPT (0.45) MAPTLMNAALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265073-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-08-24 US disclosed
US-11673878-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-06-13 US disclosed
US-20210078976-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-03-18 US disclosed
US-10889570-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078976-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885
US-20230265073-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885
US-11673878-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885
US-10889570-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.